Since IL-6 is an important mediator of inflammatory diseases, neutralizing antibodies targeting IL-6 or the IL-6 receptor, including siltuximab and tocilizumab, have been developed and approved to treat Castleman's disease and rheumatoid arthritis42, 43. The gene discussed is IL6; the disease is Castleman disease.